Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 2, 2016

Primary Completion Date

March 12, 2020

Study Completion Date

September 22, 2022

Conditions
HER2 Positive Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
Interventions
OTHER

Comprehensive Geriatric Assessment

Ancillary studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Neratinib

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (7)

91010

City of Hope Medical Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

91345

City of Hope Mission Hills, Mission Hills

91730

City of Hope Rancho Cucamonga, Rancho Cucamonga

91790

City of Hope West Covina, West Covina

92879

City of Hope Corona, Corona

93534

City of Hope Antelope Valley, Lancaster

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02673398 - Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | Biotech Hunter | Biotech Hunter